Tag Archives: Home Feature

Drugs that Reprogram Tumor Cells Introduce New Options for Blood Cancer Patients

ewc_TempleFC(2)0220150264-revA growing body of evidence supports the idea that epigenetic changes, which affect gene expression without altering the DNA sequence, play an important role in the initiation and progression of cancer. Because epigenetic therapies restore normal gene activity rather than kill cancer cells, they could be an attractive alternative for patients who cannot tolerate traditional chemotherapy. Continue Reading »

SPOTLIGHT on a Postdoctoral Associate: Q&A: Ilsiya Ibragimova, PhD

ilsiya2Ilsiya Ibragimova is a postdoctoral associate in the Cancer Epigenetics Program, which focuses on the role of epigenetic deregulation in cancer and determines how that information can improve patient outcomes. After completing her MS in biochemistry at Kazan State University in Russia, Ibragimova began her work on a PhD in molecular biology. Continue Reading »

Small-Molecule Compound Shows Promise for Treating Drug-Resistant Tumors

spheres-1-revA new compound called ONC201/TIC10 has entered clinical trials and may have the potential to treat various forms of drug-resistant cancers. Through a screen of an NCI chemical library, Wafik S. El-Deiry, MD, PhD, FACP, professor of medical oncology and deputy director for translational research at Fox Chase Cancer Center, and his colleagues discovered ONC201/TIC10. Continue Reading »